<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2023-8.4.25</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-4362</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ХИРУРГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SURGERY</subject></subj-group></article-categories><title-group><article-title>Псевдомембранозный колит, осложнённый токсическим мегаколоном, у пациентов онкологического профиля</article-title><trans-title-group xml:lang="en"><trans-title>Pseudomembranous colitis complicated by toxic megacolon in oncological patients</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7814-511X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мориков</surname><given-names>Д. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Morikov</surname><given-names>D. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мориков Дмитрий Дмитриевич – кандидат медицинских наук, доцент, доцент кафедры анестезиологии и реаниматологии; заведующий отделением анестезиологии и реанимации № 4; ассистент кафедры анестезиологии и реаниматологии </p><p>664049, г. Иркутск, Юбилейный, 100;664035, г. Иркутск, ул. Фрунзе, 32;664003, г. Иркутск, ул. Красного Восстания, 1</p></bio><bio xml:lang="en"><p>Dmitry D. Morikov – Cand. Sc. (Med), Docent, Associate Professor at the Department of Anaesthesiology and Reanimatology; Head of the Intensive Care Unit No. 4; Teaching Assistant at the Department of Anaesthesiology and Reanimatology  </p><p>Yubileyniy 100, Irkutsk 664049;Frunze str. 32, Irkutsk 664035;Krasnogo Vosstaniya str. 1, Irkutsk 664003</p></bio><email xlink:type="simple">mdd71@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карташова</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kartashova</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Карташова Виктория Владимировна – врач анестезиолог-реаниматолог отделения анестезиологии и реаниматологии №  4 </p><p>664035, г. Иркутск, ул. Фрунзе, 32</p></bio><bio xml:lang="en"><p>Victoria V. Kartashova – Anesthesiologist and Reanimatologist at the Intensive Care Unit No. 4 </p><p>Frunze str. 32, Irkutsk 664035</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шелехов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shelekhov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шелехов Алексей Владимирович – докор медицинских наук, заведующий кафедрой онкологии и лучевой терапии </p><p>664003, г. Иркутск, ул. Красного Восстания, 1</p></bio><bio xml:lang="en"><p>Aleksei V. Shelekhov – Dr. Sc. (Med.), Head of the Department of Oncology and Radiation Therapy </p><p>Krasnogo Vosstaniya str. 1, Irkutsk 664003</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Николаева</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikolaeva</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Николаева Надежда Алексеевна – врач-колопроктолог отделения колопроктологии </p><p>664035, г. Иркутск, ул. Фрунзе, 32</p></bio><bio xml:lang="en"><p>Nadezhda A. Nikolaeva – Coloproctologist at the Coloproctology Department </p><p>Frunze str. 32, Irkutsk 664035</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Иркутская государственная медицинская академия постдипломного образования – филиал ФГБОУ ВО «Российская медицинская академия непрерывного профессионального образования» Минздрава России;&#13;
ГБУЗ «Областной онкологический диспансер»;&#13;
ФГБОУ ВО «Иркутский государственный медицинский университет» Минздрава России</institution></aff><aff xml:lang="en"><institution>Irkutsk State Medical Academy of Postgraduate Education – Branch Campus of the Russian Medical Academy of Continuous Professional Education;&#13;
Irkutsk Regional Cancer Center;&#13;
Irkutsk State Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ «Областной онкологический диспансер»</institution></aff><aff xml:lang="en"><institution>Irkutsk Regional Cancer Center</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО «Иркутский государственный медицинский университет» Минздрава России</institution></aff><aff xml:lang="en"><institution>Irkutsk State Medical University</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>06</day><month>10</month><year>2023</year></pub-date><volume>8</volume><issue>4</issue><fpage>234</fpage><lpage>247</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мориков Д.Д., Карташова В.В., Шелехов А.В., Николаева Н.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Мориков Д.Д., Карташова В.В., Шелехов А.В., Николаева Н.А.</copyright-holder><copyright-holder xml:lang="en">Morikov D.D., Kartashova V.V., Shelekhov A.V., Nikolaeva N.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/4362">https://www.actabiomedica.ru/jour/article/view/4362</self-uri><abstract><p>В последние годы в литературе появляется информация о росте заболеваемости Clostridioides difficile-ассоциированной инфекции (CDI, Clostridioides difficile infection). Известно, что  наиболее часто C.  difficile, вызывающая псевдомембранозный колит (ПМК), поражает ослабленных пациентов, долго получающих лечение основной патологии. Именно поэтому ПМК наиболее часто встречается у пациентов онкологического профиля, получающих длительное и агрессивное противоопухолевое лечение, нередко сопровождающееся применением нескольких курсов антибиотиков. Следствием нерационального применения антибиотиков, некорректной терапии ПМК может быть формирование токсического мегаколона, перфорации кишечника, сепсиса, что в свою очередь чревато летальным исходом. Именно такое положение вещей вызвало наш интерес к изучению данной темы. </p><p>Неуклонный рост заболеваемости инфекцией Clostridioides difficile повсеместно делает особенно актуальным изучение проблемы CDI в мировом сообществе применительно к больным онкологического профиля, так как именно у них наиболее часто имеется широкий спектр факторов риска развития клостридиальной инфекции. </p><p>В статье представлен обзор отечественных и зарубежных источников описывающих данную патологию. Освещаются эпидемиология, патогенез, клиническая картина и современное представление о лечении CDI. </p><p>По окончании обзора нами представлен случай успешного лечения псевдомембранозного колита после закрытия стомы, осложнившегося развитием токсического мегаколона. В рамках комплексного лечения данной патологии была выполнена операция колпроктэктомии. Пациент получал респираторную, почечно-заместительную, гепатопротективную, антибиотико-и противогрибковую терапию и другое лечение.</p></abstract><trans-abstract xml:lang="en"><p>In recent years, information on the increase in the incidence of  infection associated with Clostridioides difficile (CDI) has appeared in the literature. It is known that C. difficile which causes pseudomembranous colitis (PMC) most often affects debilitated patients who receive treatment for the main pathology for a long time. That is why PMC is most common in cancer patients receiving long-term and aggressive anticancer treatment, which is often accompanied by the use of several courses of antibiotics. The result of the irrational use of antibiotics, incorrect PMC therapy may be the  formation of toxic megacolon, intestinal perforation, sepsis, which in turn is fraught with a fatal outcome. It is this state of affairs that aroused our interest in the study of this topic. </p><p>The steady increase in the incidence of Clostridioides difficile infection makes it particularly relevant to study CDI problem in relation to cancer patients, since they most often have a wide range of risk factors for developing clostridial infection. </p><p>The article presents an overview of domestic and foreign sources describing this pathology, discusses epidemiology, pathogenesis, clinical picture and current understanding of the CDI treatment. At the end of the review, we present a case of successful treatment of pseudomembranous colitis after stoma closure, which was complicated by the development of toxic megacolon. Colproctectomy was performed as part of the complex treatment of this pathology. The patient received respiratory, renal replacement, hepatoprotective, antibiotic and antifungal therapy and other treatments.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>псевдомембранозный колит</kwd><kwd>колоректальный рак</kwd><kwd>токсический мегаколон</kwd><kwd>колэктомия</kwd><kwd>C. difficile</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pseudomembranous colitis</kwd><kwd>colorectal cancer</kwd><kwd>toxic megacolon</kwd><kwd>colectomy</kwd><kwd>C. difficile</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Skally M, Bennett K, Burns K, Brennan R, Finn C, O’Connell K, et al. A decade of Clostridioides difficile infection: A constant challenge to maintain the status quo. J Hosp Infect. 2023; 135: 59-66. doi: 10.1016/j.jhin.2023.02.008</mixed-citation><mixed-citation xml:lang="en">Skally M, Bennett K, Burns K, Brennan R, Finn C, O’Connell K, et al. A decade of Clostridioides difficile infection: A constant challenge to maintain the status quo. J Hosp Infect. 2023; 135: 59-66. doi: 10.1016/j.jhin.2023.02.008</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Sadeghifard N, Salari MH, Ghassemi MR, Eshraghi S, Amin Harati F. The incidence of nosocomial toxigenic Clostridium difficile associated diarrhea in Tehran tertiary medical centers. Acta Medica Iranica. 2010; 48(5): 320-325.</mixed-citation><mixed-citation xml:lang="en">Sadeghifard N, Salari MH, Ghassemi MR, Eshraghi S, Amin Harati F. The incidence of nosocomial toxigenic Clostridium difficile associated diarrhea in Tehran tertiary medical centers. Acta Medica Iranica. 2010; 48(5): 320-325.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Белоус С.С., Сухина М.А., Халиф И.Л., Кашников В.Н., Веселов А.В., Шелыгин Ю.А. Первый опыт успешного лечения псевдомембранозного колита аутоштаммами лактобацилл. Экспериментальная и клиническая гастроэнтерология. 2018; 160(12): 47-50. doi: 10.31146/1682-8658-ecg-160-12-47-50</mixed-citation><mixed-citation xml:lang="en">Belous SS, Sukhina MA, Halif IL, Kashnikov VN, Veselov AV, Shelygin YA. The first experience of successful treatment of pseudomembranous colitis with lactobacilli auto-strains. Experimental and Clinical Gastroenterology. 2018; 160(12): 47-50. (In Russ.). doi: 10.31146/1682-8658-ecg-160-12-47-50</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Захаренко С.М. Clostridioides difficile: название новое, проблемы диагностики и терапии прежние. Альманах клинической медицины. 2022; 50(6): 377-391. doi: 10.18786/2072-0505- 2022-50-048</mixed-citation><mixed-citation xml:lang="en">Zakharenko SM. Clostridioides difficile – A new name, the old problems with diagnosis and treatment. Almanac of Clinical Medicine. 2022; 50(6): 377-391. (In Russ.). doi: 10.18786/2072-0505- 2022-50-048</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lim SC, Knight DR, Riley TV. Clostridium difficile and one health. Clin Microbiol Infect. 2020; 26(7): 857-863. doi: 10.1016/j.cmi.2019.10.023</mixed-citation><mixed-citation xml:lang="en">Lim SC, Knight DR, Riley TV. Clostridium difficile and one health. Clin Microbiol Infect. 2020; 26(7): 857-863. doi: 10.1016/j.cmi.2019.10.023</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, et al. Theepidemiology of community-acquired Clostridium difficile infection: A population-based study. Am J Gastroenterol. 2011; 107(1): 89-95. doi: 10.1038/ajg.2011.398</mixed-citation><mixed-citation xml:lang="en">Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, et al. Theepidemiology of community-acquired Clostridium difficile infection: A population-based study. Am J Gastroenterol. 2011; 107(1): 89-95. doi: 10.1038/ajg.2011.398</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Neemann K, Freifeld A. Clostridium difficile-associated diarrhea in the oncology patient. J Oncol Practice. 2017; 13(1): 25-30. doi: 10.1200/JOP.2016.018614</mixed-citation><mixed-citation xml:lang="en">Neemann K, Freifeld A. Clostridium difficile-associated diarrhea in the oncology patient. J Oncol Practice. 2017; 13(1): 25-30. doi: 10.1200/JOP.2016.018614</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ramesh AS, Munoz Tello C, Jamil D, Tran HH, Mansoor M, Butt SR et al. Role of fecal microbiota transplantation in reducing Clostridioides difficile infection-associated morbidity and mortality: A systematic review. Cureus. 2022; 14(8): e28402. doi: 10.7759/cureus.28402</mixed-citation><mixed-citation xml:lang="en">Ramesh AS, Munoz Tello C, Jamil D, Tran HH, Mansoor M, Butt SR et al. Role of fecal microbiota transplantation in reducing Clostridioides difficile infection-associated morbidity and mortality: A systematic review. Cureus. 2022; 14(8): e28402. doi: 10.7759/cureus.28402</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Harries RL, Ansell J, Codd RJ, Williams GL. A systematic review of Clostridium difficile infection following reversal of ileostomy. Colorectal Dis. 2017; 19(10): 881-887. doi: 10.1111/codi.13873</mixed-citation><mixed-citation xml:lang="en">Harries RL, Ansell J, Codd RJ, Williams GL. A systematic review of Clostridium difficile infection following reversal of ileostomy. Colorectal Dis. 2017; 19(10): 881-887. doi: 10.1111/codi.13873</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bartlett JG. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008; 46(Suppl 1): S4-S11. doi: 10.1086/521865</mixed-citation><mixed-citation xml:lang="en">Bartlett JG. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008; 46(Suppl 1): S4-S11. doi: 10.1086/521865</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Heinlen L, Ballard JD. Clostridium difficile infection. Am J Med Sci. 2010; 340(3): 247-252. doi: 10.1097/MAJ.0b013e3181e939d8</mixed-citation><mixed-citation xml:lang="en">Heinlen L, Ballard JD. Clostridium difficile infection. Am J Med Sci. 2010; 340(3): 247-252. doi: 10.1097/MAJ.0b013e3181e939d8</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Bartlett JG, Onderdonk AB, Cisneros RL, Kasper DL. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis. 1977; 136: 701-705. doi: 10.1093/infdis/136.5.701</mixed-citation><mixed-citation xml:lang="en">Bartlett JG, Onderdonk AB, Cisneros RL, Kasper DL. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis. 1977; 136: 701-705. doi: 10.1093/infdis/136.5.701</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bartlett JG, Moon N, Chang TW, Taylor N, Onderdonk AB. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology. 1978; 75: 778-782.</mixed-citation><mixed-citation xml:lang="en">Bartlett JG, Moon N, Chang TW, Taylor N, Onderdonk AB. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology. 1978; 75: 778-782.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kuipers EJ, Surawicz CM. Clostridium difficile infection. Lancet. 2008; 371(9623): 1486-1488. doi: 10.1016/S0140-6736(08)60635-2</mixed-citation><mixed-citation xml:lang="en">Kuipers EJ, Surawicz CM. Clostridium difficile infection. Lancet. 2008; 371(9623): 1486-1488. doi: 10.1016/S0140-6736(08)60635-2</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Czepiel J, Dróżdż M, Pituch H, Kuijper EJ, Perucki W, Mielimonka A, et al. Clostridium difficile infection. Eur J Clin Microbiol Infect Dis. 2019; 38(7): 1211-1221. doi: 10.1007/s10096-019-03539-6</mixed-citation><mixed-citation xml:lang="en">Czepiel J, Dróżdż M, Pituch H, Kuijper EJ, Perucki W, Mielimonka A, et al. Clostridium difficile infection. Eur J Clin Microbiol Infect Dis. 2019; 38(7): 1211-1221. doi: 10.1007/s10096-019-03539-6</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect. 2009; 15(12): 1053-1066. doi: 10.1111/j.1469-0691.2009.03098.x</mixed-citation><mixed-citation xml:lang="en">Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect. 2009; 15(12): 1053-1066. doi: 10.1111/j.1469-0691.2009.03098.x</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Buonomo EL, Petri WA. The microbiota and immune response during Clostridium difficile infection. Anaerobe. 2016; (41): 79-84. doi: 10.1016/j.anaerobe.2016.05.009</mixed-citation><mixed-citation xml:lang="en">Buonomo EL, Petri WA. The microbiota and immune response during Clostridium difficile infection. Anaerobe. 2016; (41): 79-84. doi: 10.1016/j.anaerobe.2016.05.009</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">von Eichel-Streiber C, Warfolomeow I, Knautz D, Sauerborn M, Hadding U. Morphological changes in adherent cells induced by Clostridium difficile toxins. Biochem Soc Transact. 1991; 19(4): 1154-1160. doi: 10.1042/bst0191154</mixed-citation><mixed-citation xml:lang="en">von Eichel-Streiber C, Warfolomeow I, Knautz D, Sauerborn M, Hadding U. Morphological changes in adherent cells induced by Clostridium difficile toxins. Biochem Soc Transact. 1991; 19(4): 1154-1160. doi: 10.1042/bst0191154</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Thibault A, Miller MA, Gaese C. Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak. Infect Control Hosp Epidemiol. 1991; 12(6): 345-348. doi: 10.1086/646354</mixed-citation><mixed-citation xml:lang="en">Thibault A, Miller MA, Gaese C. Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak. Infect Control Hosp Epidemiol. 1991; 12(6): 345-348. doi: 10.1086/646354</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kim J, Pai H, Seo MR, Kang JO. Epidemiology and clinical characteristics of Clostridium difficile infection in a Korean Tertiary Hospital. J Kor Med Sci. 2011; 10(26): 1258-1264. doi: 10.3346/jkms.2011.26.10.1258</mixed-citation><mixed-citation xml:lang="en">Kim J, Pai H, Seo MR, Kang JO. Epidemiology and clinical characteristics of Clostridium difficile infection in a Korean Tertiary Hospital. J Kor Med Sci. 2011; 10(26): 1258-1264. doi: 10.3346/jkms.2011.26.10.1258</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis. 2005; 40: 265-272. doi: 10.1086/427113</mixed-citation><mixed-citation xml:lang="en">McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis. 2005; 40: 265-272. doi: 10.1086/427113</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Lyerly DM, Barroso LA, Wilkins TD. Identification of the latex test-reactive protein of Clostridium difficile as glutamate dehydrogenase. J Clin Microbiol. 1991; 29: 2639-2642. doi: 10.1128/jcm.29.11.2639-2642.1991</mixed-citation><mixed-citation xml:lang="en">Lyerly DM, Barroso LA, Wilkins TD. Identification of the latex test-reactive protein of Clostridium difficile as glutamate dehydrogenase. J Clin Microbiol. 1991; 29: 2639-2642. doi: 10.1128/jcm.29.11.2639-2642.1991</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet. 1998; 351: 633-636. doi: 10.1016/S0140-6736(97)08062-8</mixed-citation><mixed-citation xml:lang="en">Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet. 1998; 351: 633-636. doi: 10.1016/S0140-6736(97)08062-8</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun. 1994; 62: 384-389. doi: 10.1128/iai.62.2.384-389.1994</mixed-citation><mixed-citation xml:lang="en">Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun. 1994; 62: 384-389. doi: 10.1128/iai.62.2.384-389.1994</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013; 108(4): 478-498; quiz 499. doi: 10.1038/ajg.2013.4</mixed-citation><mixed-citation xml:lang="en">Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013; 108(4): 478-498; quiz 499. doi: 10.1038/ajg.2013.4</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Prendergast TM, Marini CP, D’Angelo AJ. Surgical patients with pseudomembranous colitis: Factors affecting prognosis. Surgery. 1994; 116: 768-774; discussion 774-775.</mixed-citation><mixed-citation xml:lang="en">Prendergast TM, Marini CP, D’Angelo AJ. Surgical patients with pseudomembranous colitis: Factors affecting prognosis. Surgery. 1994; 116: 768-774; discussion 774-775.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum. 1995; 38: 350-354. doi: 10.1007/BF02054220</mixed-citation><mixed-citation xml:lang="en">Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum. 1995; 38: 350-354. doi: 10.1007/BF02054220</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Brown CH, Ferrante WA, Davis WD. Toxic dilatation of the colon complicating pseudomembranous enterocolitis. Am J Digest Dis. 1968; 13(9): 813-821. doi: 10.1007/BF02233098</mixed-citation><mixed-citation xml:lang="en">Brown CH, Ferrante WA, Davis WD. Toxic dilatation of the colon complicating pseudomembranous enterocolitis. Am J Digest Dis. 1968; 13(9): 813-821. doi: 10.1007/BF02233098</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Trudel JL, Deschenes M, Mayrand S, Barkun AN. Toxic megacolon complicating pseudomembranous enterocolitis. Dis Colon Rectum. 1995; 38: 1033-1038. doi: 10.1007/BF02133974</mixed-citation><mixed-citation xml:lang="en">Trudel JL, Deschenes M, Mayrand S, Barkun AN. Toxic megacolon complicating pseudomembranous enterocolitis. Dis Colon Rectum. 1995; 38: 1033-1038. doi: 10.1007/BF02133974</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) – A systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis. 2021; 21(1): 456. doi: 10.1186/s12879-021-06147-y</mixed-citation><mixed-citation xml:lang="en">Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) – A systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis. 2021; 21(1): 456. doi: 10.1186/s12879-021-06147-y</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Kyne L, Warny M, Qamar A, Kelly CP. Association betweenantibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001; 357: 189-193. doi: 10.1016/S0140-6736(00)03592-3</mixed-citation><mixed-citation xml:lang="en">Kyne L, Warny M, Qamar A, Kelly CP. Association betweenantibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001; 357: 189-193. doi: 10.1016/S0140-6736(00)03592-3</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005; 40: 1591-1597. doi: 10.1086/430315</mixed-citation><mixed-citation xml:lang="en">Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005; 40: 1591-1597. doi: 10.1086/430315</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Chung MS, Kim J, Kang JO, Pai H. Impact of malignancy on Clostridium difficile infection. Eur J Clin Microbiol Infect Dis. 2016; 35(11): 1771-1776. doi: 10.1007/s10096-016-2725-6</mixed-citation><mixed-citation xml:lang="en">Chung MS, Kim J, Kang JO, Pai H. Impact of malignancy on Clostridium difficile infection. Eur J Clin Microbiol Infect Dis. 2016; 35(11): 1771-1776. doi: 10.1007/s10096-016-2725-6</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Shen B, Lin S, Shueng P, Chou Y, Tseng L, Hsieh C. Pseudomembranous colitis with in radiotherapy field following concurrent chemoradiation therapy: A case report. Onco Targets Ther. 2013; 6: 25-28. doi: 10.2147/OTT.S40145</mixed-citation><mixed-citation xml:lang="en">Shen B, Lin S, Shueng P, Chou Y, Tseng L, Hsieh C. Pseudomembranous colitis with in radiotherapy field following concurrent chemoradiation therapy: A case report. Onco Targets Ther. 2013; 6: 25-28. doi: 10.2147/OTT.S40145</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Peterz A, Shlomo BI, Nitzan O, Bonavina L, Schaffer MP, Schaffer M. Clostridium difficile infection: Association with chemotherapy, radiation therapy and targeting therapy treatments. Curr Med Chem. 2016; 23(39). doi: 10.2174/0929867323666161028162018</mixed-citation><mixed-citation xml:lang="en">Peterz A, Shlomo BI, Nitzan O, Bonavina L, Schaffer MP, Schaffer M. Clostridium difficile infection: Association with chemotherapy, radiation therapy and targeting therapy treatments. Curr Med Chem. 2016; 23(39). doi: 10.2174/0929867323666161028162018</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Delgado A, Reveles IA, Cabello FT, Reveles KR. Poorer outcomes among cancer patients diagnosed with Clostridium difficile infections in United States community hospitals. BMC Infect Dis. 2017; 17(1): 448. doi: 10.1186/s12879-017-2553-z</mixed-citation><mixed-citation xml:lang="en">Delgado A, Reveles IA, Cabello FT, Reveles KR. Poorer outcomes among cancer patients diagnosed with Clostridium difficile infections in United States community hospitals. BMC Infect Dis. 2017; 17(1): 448. doi: 10.1186/s12879-017-2553-z</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Kawamoto S, Horton KM, Fishman EK. Pseudomembranouscolitis: Can CT predict which patients will need surgical intervention? J Comput Assist Tomogr. 1999; 23: 79-85. doi: 10.1097/00004728-199901000-00017</mixed-citation><mixed-citation xml:lang="en">Kawamoto S, Horton KM, Fishman EK. Pseudomembranouscolitis: Can CT predict which patients will need surgical intervention? J Comput Assist Tomogr. 1999; 23: 79-85. doi: 10.1097/00004728-199901000-00017</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Morales Chamorro RM, Serrano Blanch R, Méndez Vidal MJ, Gómez España MA, Rubio Pérez MJ, de la Haba Rodríguez J, et al. Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil. Clin Transl Oncol. 2005; 7(6): 258-261. doi: 10.1007/BF02710173</mixed-citation><mixed-citation xml:lang="en">Morales Chamorro RM, Serrano Blanch R, Méndez Vidal MJ, Gómez España MA, Rubio Pérez MJ, de la Haba Rodríguez J, et al. Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil. Clin Transl Oncol. 2005; 7(6): 258-261. doi: 10.1007/BF02710173</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Olson MM, Shanholtzer CJ, Lee JT Jr, Gerding DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982–1991. Infect Control Hosp Epidemiol. 1994; 15: 371-381. doi: 10.1086/646934</mixed-citation><mixed-citation xml:lang="en">Olson MM, Shanholtzer CJ, Lee JT Jr, Gerding DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982–1991. Infect Control Hosp Epidemiol. 1994; 15: 371-381. doi: 10.1086/646934</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31(5): 431-455. doi: 10.1086/651706</mixed-citation><mixed-citation xml:lang="en">Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31(5): 431-455. doi: 10.1086/651706</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Parmar SR, Bhatt V, Yang J, Zhang Q, Schuster M. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. J Oncol Pharm Pract. 2013; 20(3): 172-182. doi: 10.1177/1078155213490004</mixed-citation><mixed-citation xml:lang="en">Parmar SR, Bhatt V, Yang J, Zhang Q, Schuster M. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. J Oncol Pharm Pract. 2013; 20(3): 172-182. doi: 10.1177/1078155213490004</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Tsuchida K, Hayashi T, Hayashi S, Sawazaki S, Jin Y, Hasuo K, et al. A case of pseudomembranous colitis with febrile neutropenia induced by chemotherapy and effectively treated by vancomycin enemas. Gan To Kagaku Ryoho. Cancer &amp; Chemotherapy. 2010; 37(9): 1821-1823.</mixed-citation><mixed-citation xml:lang="en">Tsuchida K, Hayashi T, Hayashi S, Sawazaki S, Jin Y, Hasuo K, et al. A case of pseudomembranous colitis with febrile neutropenia induced by chemotherapy and effectively treated by vancomycin enemas. Gan To Kagaku Ryoho. Cancer &amp; Chemotherapy. 2010; 37(9): 1821-1823.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Bolton RP, Culshaw MA. Faecal metronidazole concentrationsduring oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut. 1986; 27: 1169-1172. doi: 10.1136/gut.27.10.1169</mixed-citation><mixed-citation xml:lang="en">Bolton RP, Culshaw MA. Faecal metronidazole concentrationsduring oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut. 1986; 27: 1169-1172. doi: 10.1136/gut.27.10.1169</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: Case series and review of the literature. Clin Infect Dis. 2002; 35: 690. doi: 10.1086/342334</mixed-citation><mixed-citation xml:lang="en">Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: Case series and review of the literature. Clin Infect Dis. 2002; 35: 690. doi: 10.1086/342334</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Rubin DT, Sohi S, Glathar M, Thomas T, Yadron N, Surma BL. Rifaximin is effective for the treatment of Clostridium difficile-associated diarrhea: Results of an open-label pilot study. Gastroenterol Res Pract. 2011; 2011: 106978. doi: 10.1155/2011/106978</mixed-citation><mixed-citation xml:lang="en">Rubin DT, Sohi S, Glathar M, Thomas T, Yadron N, Surma BL. Rifaximin is effective for the treatment of Clostridium difficile-associated diarrhea: Results of an open-label pilot study. Gastroenterol Res Pract. 2011; 2011: 106978. doi: 10.1155/2011/106978</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Khoruts A, Staley C, Sadowsky MJ. Faecal microbiota transplantation for Clostridioides difficile: Mechanisms and pharmacology. Nat Rev Gastroenterol Hepatol. 2021; 18(1): 67-80. doi: 10.1038/s41575-020-0350-4</mixed-citation><mixed-citation xml:lang="en">Khoruts A, Staley C, Sadowsky MJ. Faecal microbiota transplantation for Clostridioides difficile: Mechanisms and pharmacology. Nat Rev Gastroenterol Hepatol. 2021; 18(1): 67-80. doi: 10.1038/s41575-020-0350-4</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Mittal C, Miller N, Meighani A, Hart BR, John A, Ramesh M. Fecal microbiota transplant for recurrent Clostridium difficile infection after peripheral autologous stem cell transplant for diffuse large B-cell lymphoma. Bone Marrow Transplantation. 2015; 50(7): 1010-1010. doi: 10.1038/bmt.2015.85</mixed-citation><mixed-citation xml:lang="en">Mittal C, Miller N, Meighani A, Hart BR, John A, Ramesh M. Fecal microbiota transplant for recurrent Clostridium difficile infection after peripheral autologous stem cell transplant for diffuse large B-cell lymphoma. Bone Marrow Transplantation. 2015; 50(7): 1010-1010. doi: 10.1038/bmt.2015.85</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Neemann K, Eichele DD, Smith PW, Bociek R, Akhtari M, Freifeld A. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl Infect Dis. 2012; 14(6): E161-E165. doi: 10.1111/tid.12017</mixed-citation><mixed-citation xml:lang="en">Neemann K, Eichele DD, Smith PW, Bociek R, Akhtari M, Freifeld A. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl Infect Dis. 2012; 14(6): E161-E165. doi: 10.1111/tid.12017</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother. 2008; 52(11): 4163-4165. doi: 10.1128/AAC.00476-08</mixed-citation><mixed-citation xml:lang="en">Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother. 2008; 52(11): 4163-4165. doi: 10.1128/AAC.00476-08</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Buddle JE, Fagan RP. Pathogenicity and virulence of Clostridioides difficile. Virulence. 2023; 14(1): 2150452. doi: 10.1080/21505594.2022.2150452</mixed-citation><mixed-citation xml:lang="en">Buddle JE, Fagan RP. Pathogenicity and virulence of Clostridioides difficile. Virulence. 2023; 14(1): 2150452. doi: 10.1080/21505594.2022.2150452</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021; 73(5): 755-757. doi: 10.1093/cid/ciab718</mixed-citation><mixed-citation xml:lang="en">Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021; 73(5): 755-757. doi: 10.1093/cid/ciab718</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Lipsett PA, Samantaray DK, Tam ML. Pseudomembranous colitis: A surgical disease? Surgery. 1994; 116: 491-496.</mixed-citation><mixed-citation xml:lang="en">Lipsett PA, Samantaray DK, Tam ML. Pseudomembranous colitis: A surgical disease? Surgery. 1994; 116: 491-496.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Koss K, Clark MA, Sanders DS. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis. 2006; 8: 149-154. doi: 10.1111/j.1463-1318.2005.00876.x</mixed-citation><mixed-citation xml:lang="en">Koss K, Clark MA, Sanders DS. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis. 2006; 8: 149-154. doi: 10.1111/j.1463-1318.2005.00876.x</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Longo WE, Mazuski JE, Virgo KS. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum. 2004; 47: 1620-1626. doi: 10.1007/s10350-004-0672-2</mixed-citation><mixed-citation xml:lang="en">Longo WE, Mazuski JE, Virgo KS. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum. 2004; 47: 1620-1626. doi: 10.1007/s10350-004-0672-2</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Klipfel AA, Schein M, Fahoum B. Acute abdomen and Clostridium difficile colitis: Still a lethal combination. Dig Surg. 2000; 17: 160-163. doi: 10.1159/000018821</mixed-citation><mixed-citation xml:lang="en">Klipfel AA, Schein M, Fahoum B. Acute abdomen and Clostridium difficile colitis: Still a lethal combination. Dig Surg. 2000; 17: 160-163. doi: 10.1159/000018821</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Sailhamer EA, Carson K, Chang Y, Zacharias N, Spaniolas K, Tabbara M, et al. Fulminant Clostridium difficile colitis: Patterns of care and predictors of mortality. Arch Surg. 2009; 144: 433-439; discussion 439-440.</mixed-citation><mixed-citation xml:lang="en">Sailhamer EA, Carson K, Chang Y, Zacharias N, Spaniolas K, Tabbara M, et al. Fulminant Clostridium difficile colitis: Patterns of care and predictors of mortality. Arch Surg. 2009; 144: 433-439; discussion 439-440.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, et al. ACG clinical guidelines: Prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021; 116(6): 1124-1147. doi: 10.14309/ajg.0000000000001278</mixed-citation><mixed-citation xml:lang="en">Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, et al. ACG clinical guidelines: Prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021; 116(6): 1124-1147. doi: 10.14309/ajg.0000000000001278</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmed N, Kuo YH. Outcomes of total versus partial colectomy in fulminant Clostridium difficile colitis: A propensity matched analysis. World J Emerg Surg. 2022; 17(1): 11. doi: 10.1186/s13017-022-00414-2</mixed-citation><mixed-citation xml:lang="en">Ahmed N, Kuo YH. Outcomes of total versus partial colectomy in fulminant Clostridium difficile colitis: A propensity matched analysis. World J Emerg Surg. 2022; 17(1): 11. doi: 10.1186/s13017-022-00414-2</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Peprah D, Chiu AS, Jean RA, Pei KY. Comparison of outcomes between total abdominal and partial colectomy for the management of severe, complicated Clostridium difficile infection. J Am Coll Surg. 2019; 228(6): 925-930. doi: 10.1016/j.jamcollsurg.2018.11.015</mixed-citation><mixed-citation xml:lang="en">Peprah D, Chiu AS, Jean RA, Pei KY. Comparison of outcomes between total abdominal and partial colectomy for the management of severe, complicated Clostridium difficile infection. J Am Coll Surg. 2019; 228(6): 925-930. doi: 10.1016/j.jamcollsurg.2018.11.015</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Sartelli M, Di Bella S, McFarland LV, Khanna S, FuruyaKanamori L, Abuzeid N, et al. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg. 2019; 14: 8. doi: 10.1186/s13017-019-0228-3</mixed-citation><mixed-citation xml:lang="en">Sartelli M, Di Bella S, McFarland LV, Khanna S, FuruyaKanamori L, Abuzeid N, et al. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg. 2019; 14: 8. doi: 10.1186/s13017-019-0228-3</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Pepin J, Vo TT, Boutros M, Marcotte E, Dial S, Dubé S, et al. Risk factors for mortality following emergency colectomy for fulminant Clostridium difficile infection. Dis Colon Rectum. 2009; 52: 400-405. doi: 10.1007/DCR.0b013e31819a69aa</mixed-citation><mixed-citation xml:lang="en">Pepin J, Vo TT, Boutros M, Marcotte E, Dial S, Dubé S, et al. Risk factors for mortality following emergency colectomy for fulminant Clostridium difficile infection. Dis Colon Rectum. 2009; 52: 400-405. doi: 10.1007/DCR.0b013e31819a69aa</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Шелыгин Ю.А., Алёшкин В.А., Сухина М.А., Миронов А.Ю., Брико Н.И., Козлов Р.С., и др. Клинические рекомендации Национальной ассоциации специалистов по контролю инфекций, связанных с оказанием медицинской помощи, и общероссийской общественной некоммерческой организации «Ассоциация колопроктологов России» по диагностике, лечению и профилактике Clostridium difficile-ассоциированной диареи (CDI). Колопроктология. 2018; (3): 7-23. doi: 10.33878/2073-7556-2018-0-3-7-23</mixed-citation><mixed-citation xml:lang="en">Shelygin YuA, Aleshkin VA, Sukhina MA, Mironov AYu, Briko NI, Kozlov RS, et al. Clinical recommendations of the National Association of Infection Control Specialists Associated with the Medical Care Provision and the Association of Coloproctologists of Russia for the diagnosis, treatment and prevention of Clostridium difficile-associated diarrhea (CDI). Koloproktologia. 2018; (3): 7-23. (In Russ.). doi: 10.33878/2073-7556-2018-0-3-7-23</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Zafar AB, Gaydos LA, Furlong WB, Nguyen MH, Mennonna PA. Effectiveness of infection control program in controlling nosocomial Clostridium difficile. Am J Infect Control. 1998; 26: 588-93. doi: 10.1053/ic.1998.v26.a84773</mixed-citation><mixed-citation xml:lang="en">Zafar AB, Gaydos LA, Furlong WB, Nguyen MH, Mennonna PA. Effectiveness of infection control program in controlling nosocomial Clostridium difficile. Am J Infect Control. 1998; 26: 588-93. doi: 10.1053/ic.1998.v26.a84773</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
